Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints

Drug Resistance Updates

Volumn 12, Issue 6, 2009, Pages 141-147

  Verweij, Paul E ^a   Howard, Susan J ^b   Melchers, Willem J G ^a   Denning, David W ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

AMINO ACID SUBSTITUTION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; AZOLE RESISTANCE; CODON; CORRELATION ANALYSIS; CYP51A GENE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SENSITIVITY; FUNGAL GENE; FUNGAL STRAIN; FUNGUS CULTURE; GENE MUTATION; GENOTYPE; HUMAN; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NOMENCLATURE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; THRUSH; TREATMENT FAILURE; TREATMENT RESPONSE;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, FUNGAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; TERMINOLOGY AS TOPIC;

EID: 70749088981     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2009.09.002     Document Type: Article

References (56)

1. Arendrup M.C., Perkhofer S., Howard S.J., Garcia-Effron G., Vishukumar A., Perlin D., and Lass-Flörl C. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles vs. echinocandins. Antimicrob. Agents Chemother. 52 (2008) 3504-3511
2. Balajee S.A., Gribskov J.L., Hanley E., Nickle D., and Marr K.A. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4 (2005) 625-632
3. Chen J., Li H., Li R., Bu D., and Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55 (2005) 31-37
4. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B acquired resistance to itraconazole. Scand. J. Infect. Dis. 29 (1997) 509-512
5. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., Helfgott D., Holowiecki J., Stockelberg D., Goh Y.T., Petrini M., Hardalo C., Suresh R., and Angulo-Gonzalez D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356 (2007) 348-359
6. Cuenca-Estrella M., Moore C.B., Barchiesi F., Bille J., Chryssanthou E., Denning D.W., Donnelly J.P., Dromer F., Dupont B., Rex J.H., Richardson M.D., Sancak B., Verweij P.E., Rodríguez-Tudela J.L., and AFST Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 9 (2003) 467-474
7. Cuenca-Estrella M., Arendrup M.C., Chryssanthou E., Dannaoui E., Lass-Florl C., Sandven P., Velegraki A., Rodriguez-Tudela J.L., and AFST Subcommittee of EUCAST. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 13 (2007) 1018-1022
8. Dannaoui E., Borel E., Monier M.F., Piens M.A., Picot S., and Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47 (2001) 333-340
9. Denning D.W., Radford S.A., Oakley K.L., Hall L., Johnson E.M., and Warnock D.W. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40 (1997) 401-414
10. Denning D.W., Venkateswarlu K., Oakley K.L., Anderson M.J., Manning N.J., Stevens D.A., Warnock D.W., and Kelly S.L. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41 (1997) 1364-1368
11. Denning D.W., Riniotis K., Dobrashian R., and Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin. Infect. Dis. 37 Suppl. 3 (2003) S265-S280
12. Diaz-Guerra T.M., Mellado E., Cuenca-Estrella M., and Rodriguez-Tudela J.L. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47 (2003) 1120-1124
13. Guinea J., Recio S., Peláez T., Torres-Narbona M., and Bouza E. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob. Agents Chemother. 52 (2008) 3444-3446
14. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., Kern W.V., Marr K.A., Ribaud P., Lortholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P., Durand C., Caillot D., Thiel E., Chandrasekar P.H., Hodges M.R., Schlamm H.T., Troke P.F., de Pauw B., and Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347 (2002) 408-415
15. Hodiamont C.J., Dolman K.M., ten Berge R.J.M., Melchers W.J.G., Verweij P.E., et al. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with longterm oral posaconazole and surgery. Med. Mycol. 47 (2009) 217-220
16. Hope W.W., Warn P.A., Sharp A., Howard S., Kasai M., Louie A., Walsh T.J., Drusano G.L., and Denning D.W. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob. Agents Chemother. 50 (2006) 3680-3688
17. Howard S.J., Moore C.B., and Denning DW. Azole resistance in Aspergillus niger. 2nd Advances Against Aspergillosis. Athens, Greece (2006)
18. Howard S.J., Webster I., Moore C.B., Gardiner R.E., Park S., Perlin D.S., and Denning D.W. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28 (2006) 450-453
19. Howard S.J., Albarrag A., Anderson M.J., Gardiner R.E., Park S., Perlin D., and Denning D.W. Azole resistance in clinical Aspergillus fumigatus strains. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (2006)
20. Howard S.J., Harrison E., Bowyer P., and Denning DW. Molecular identification of clinical black Aspergillus isolates and azole resistance. 3rd Advances Against Aspergillosis. Miami, USA (2008)
21. Howard S.J., Cesar D., Anderson M.J., Albarrag A.M., Fisher M., Pasqualotto A.C., Laverdiere M., Arendrup M.C., Perlin D.S., and Denning D.W. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15 (2009) 1068-1076
22. Howard SJ, Pasqualotto AC, Denning DW. 2009b. Azole resistance in ABPA and Aspergillus bronchitis. Clin Microbiol. Infect. 2009, in press.
23. Johnson E., Oakley K.L., Radford S., Moore C.B., Warn P., Warnock D.W., and Denning D.W. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome of in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45 (1999) 85-93
24. Kontoyiannis D.P., Lewis R.E., May G.S., Osherov N., and Rinaldi M.G. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 45 (2002) 406-407
25. Krishnan P.U., Miles K., and Shetty N. Detection of methicillin and mupirocin resistance in Staphylococcus aureus isolates using conventional and molecular methods: a descriptive study from a burns unit with high prevalence of MRSA. J. Clin. Pathol. 55 (2002) 745-748
26. Lagrou K., De Vleeschouwer J., Meerseman W., et al. Triazole resistance among 229 clinical Aspergillus fumigatus isolates. 3rd Advances Against Aspergillosis. Miami 230, USA (2008) Abstract 33
27. Lass-Florl C., and Perkhofer S. In vitro susceptibility-testing in Aspergillus species. Mycoses 51 (2008) 437-446
28. Manavathu E.K., Cutright J., and Chandrasekar P.H. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents. J. Clin. Microbiol. 37 (1999) 858-861
29. Manavathu E.K., Baskaran I., Krishnan S., Alangaden G., and Chandrasekar PH. Cytochrome P450 14-alpha-sterol demethylase mutation dependent triazole cross-resistance in Aspergillus fumigatus. 43rd Interscience Conference on Antimicrobial Agents and ChemotherapyPC Chicago, USA (2003)
30. Mann P.A., Parmegiani R.M., Wei S.Q., et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob. Agents Chemother. 47 (2003) 577-581
31. Mavridou E., Mouton J.W., Brüggemann R.J., Melchers W.J.G., and Verweij P.E. Efficacy of posaconazole against clinical aspergillus fumigatus isolates with mutations in the cyp51a gene. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, USA (2008) abstract M-2171
32. Mellado E., Garcia-Effron G., Alcazar-Fuoli L., Cuenca-Estrella M., and Rodriguez-Tudela J.L. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48 (2004) 2747-2750
33. Mellado E., Garcia-Effron G., Alcázar-Fuoli L., Melchers W.J., Verweij P.E., Cuenca-Estrella M., and Rodríguez-Tudela J.L. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51 (2007) 1897-1904
34. Mosquera J., and Denning D.W. Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 46 (2002) 556-557
35. Mosquera J., Warn P.A., Morrissey J., Moore C.B., Gil-Lamaignere C., and Denning D.W. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob. Agents Chemother. 45 (2001) 1456-1462
36. Nascimento A.M., Goldman G.H., Park S., et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47 (2003) 1719-1726
37. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi (2002), National Committee for Clinical Laboratory Standards, Wayne, PA Approved standard M38-A
38. Oakley K.L., Morrissey G., and Denning D.W. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41 (1997) 1504-1507
39. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., and Diekema D.J. In Vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46 (2008) 2568-2572
40. Rambali B., Fernandez J.A., Van Nuffel L., Woestenborghs F., Baert L., Massart D.L., and Odds F.C. Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. J. Antimicrob. Chemother. 48 (2001) 163-177
41. Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., Lancaster M., Odds F.C., Rinaldi M.G., Walsh T.J., and Barry A.L. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24 (1997) 235-247
42. Rodríguez-Tudela J.L., Almirante B., Rodríguez-Pardo D., Laguna F., Donnelly J.P., Mouton J.W., Pahissa A., and Cuenca-Estrella M. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51 (2007) 3599-3604
43. Subcommittee of Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds (2007)
44. Slaven J.W., Anderson M.J., Sanglard D., et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet. Biol. 36 (2002) 199-206
45. Snelders E., van der Lee H.A.L., Kuijpers J., Rijs A.J.M.M., Varga J., Samson R.A., Mellado E., Melchers W.J.G., and Verweij P.E. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5 (2008) e219
46. Snelders E., Huis In 't Veld R.A., Rijs A.J., Kema G.H., Melchers W.J., and Verweij P.E. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75 (2009) 4053-4057
47. Steinbach W.J., Benjamin Jr. D.K., Kontoyiannis D.P., Perfect J.R., Lutsar I., Marr K.A., Lionakis M.S., Torres H.A., Jafri H., and Walsh T.J. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis. 39 (2004) 192-198
48. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., Greinix H., Morais de Azevedo W., Reddy V., Boparai N., Pedicone L., Patino H., and Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356 (2007) 335-347
49. Varga J., Houbraken J., Van Der Lee H.A., Verweij P.E., and Samson R.A. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot. Cell 7 (2008) 630-638
50. Van der Linden J.W.M., Snelders E., Debets Y., Kampinga G.A., Kuijper E., Mattson E., Rijnders B., van Tiel F.H., Visser C., Melchers W.J.G., and Verweij PE. Prospective study of the prevalence of azole resistance in aspergillus species in the Netherlands. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (2008) abstract M-1718
51. Van der Linden J.W.M., Jansen R.R., Bresters D., Visser C.E., Geerlings S.E., Kuijper E.J., Melchers W.J.G., and Verweij P.E. Azole resistant central nervous system aspergillosis. Clin. Infect. Dis. 48 (2009) 1441-1458
52. Verweij P.E., Mellado E., and Melchers W.J. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356 (2007) 1481-1483
53. Walsh T.J., Petraitis V., Petraitiene R., Field-Ridley A., Sutton D., Ghannoum M., Sein T., Schaufele R., Peter J., Bacher J., Casler H., Armstrong D., Espinel-Ingroff A., Rinaldi M.G., and Lyman C.A. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188 (2003) 305-319
54. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., Stevens D.A., van Burik J.A., Wingard J.R., and Patterson T.F. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46 (2008) 327-360
55. Warris A., Weemaes C.M., and Verweij P.E. Multidrug resistance in Aspergillus fumigatus. N. Engl. J. Med. 347 (2002) 2173-2174
56. Xiao L., Madison V., Chau A.S., Loebenberg D., Palermo R.E., and McNicholas P.M. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48 (2004) 568-574